09-13-04

1 Lu

PTO/SB/21 (02-04) PTIOTSB27 (UZ-09)
Approved for use through 07/31/2006, OMB 0551-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it displays a valid OMB control number. Application Number 10/696,282 Filing Date October 29, 2003 TRANSMITTAL First Named Inventor Wilson et al FORM 1835 (to be used for all correspondence after initial filing) Examiner Name Brian A. Whiteman Attomey Docket Number GNV31BUSA/UPN-K1774DIV1 Total Number of Pages in This Submission (Check all that apply) **FNCLOSURES** After Allowance communication to Technology Center (TC) Drawing(s) Fee Transmittal Form Appeal Communication to Board of Appeals and Interferences Licensing-related Papers Appeal Communication to TC Fee Attached (Appeal Notice, Brief, Reply Brief) Petition Amendment/Reply Proprietary Information Petition to Convert to a Provisional Application After Final Power of Attorney, Revocation Status Letter Change of Correspondence Address Other Enclosure(s) (please Affidavits/declaration(s) Identify below): Terminal Disclaimer Extension of Time Request Request for Refund 2-Documents xpress Abandonment Request (がわり、エルシ) Information Disclosure Statement CD. Number of CD(s) Remarks Certified Copy of Priority Express Mail No. ER635161336US Document(s) Response to Missing Parts/ Customer No 00270 Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT HOWSON AND HOWSON Firm Cathy A. Kodroff Individual name Signature

## September 16, 2004 CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with nereuy ceruly und the correspondence is being lecamine transmitted to the upper of deposited with the united states rostal service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name		
	Date	
Signature		

Date

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTC processes) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to 2 hours to complete including in process) an application. Confidentially is governed by 38 U.S.C. 122 and 37 CFR 1.4. This collection is estimated to 2 hours to complete applications of the USPTC. Time will vary depending upon the individual case. Any comments adhering, preparing, and submitting the completed subject to the Chief Information and amount of time you require to complete his formation. The confidential control of the your require to complete his formation. On the USPTC processes the Chief Information Chief. U.S. Department of Confidential Chief. 2013 14 (1997) 14 ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



## GNV31BUSA/UPN-K1774DIV1

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/696,282

Confirmation No.: 7675

Applicant

: Wilson et al

Filed

: October 29, 2003

TC/A.U.

: 1635

Examiner

: Brian A. Whiteman

Customer No.

: 00270

Title

: ADENO-ASSOCIATED VIRUS SEROTYPE 1 NUCLEIC ACID SEQUENCES, VECTORS AND

HOST CELLS CONTAINING SAME

Mail Stop Amendment Commissioner for Patents P.O. Box 1450

Alexandria, VA 22313-1450

## FIFTH SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sirs:

Applicant submits to the Examiner the attached Form PTO/SB/08B document listing and this paper pursuant to 37 CFR § 1.56 and § 1.97-1.98. Form PTO/SB/08B is attached and copies of the documents are enclosed herewith. This Information Disclosure Statement is submitted more than three months from the filing date of this application and before the receipt of a first Office Action on the merits. Therefore, no fees are believed due.

The Director is hereby authorized to charge any deficiency in any fees due with the filing of this paper or credit any overpayment in any fees to our Deposit Account Number 08-3040.

The Examiner is respectfully requested to consider the enclosed document identified in this paper and in the attached Form PTO/SB/08B during the course of examination of this application.

Respectfully submitted,

HOWSON AND HOWSON Attorneys for Applicant

Cathy A Kodroff

Registration No. 33,980 Spring House Corporate Center

Box 457

Spring House, PA 19477 Phone: (215) 540-9200

Fax: (215) 540-5818



PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Tademark Office; U.S. DEPARTMENT OF COMMERCE rion of information unless it contains a valid OMB control number

Under the Paperwon Country of 1999, No.		Complete if Known		
Substitute for form 1449/PTO			Application Number	10/696,282
INFORMATION DISCLOSURE STATEMENT BY APPLICANT  (Use as many sheets as necessary)		Filing Date	October 29, 2003	
		First Named Inventor	Wilson et al	
		Group Art Unit	1635	
		Examiner Name	Brian A. Whiteman	
	of	1	Attorney Docket Number	GNV31BUSA/K1774DIV1
Sheet 1	or	1		

NONPATENT LITERATURE DOCUMENTS Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of

Examiner Initials*	Cite No.1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title or the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	LLL	ZHI ET AL, Increased Antigen-Specific Humoral Response by Adenoviral Vector Prime and Adeno-Associated Viral Vector Boost, Abstract 569, 7 <sup>th</sup> Annual Meeting of the American Society of Gene Therapy [June 2-6, 2004] Minneapolis,	
		Minnesota, (e-publ. May 2, 2004)	-
	MMM	(e-publ. May 2, 2004)  BOYER ET AL, Anti-SARS Humoral And Cellylar Immunity Evoked by  Adenovirus Vector Expressing Spike Glycoprotein from SARS Coronavirus,  Abstract 558, 7th Annual Meeting of the American Society of Gene Therapy [June 2-6, 2004] Minneapolis, Minnesota, (e-publ. May 2, 2004)	
		2-0, 2004] Timicapono,	
			-
	-		1
			$\overline{}$

Examiner Signature \* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form win nex communication to applicant.

Applicant: on the conformance of the conformanc Patents, P.O. Box 1450, Alexandria, VA 22313-1450.